sotorasib

AXP000023.1 · Targeted small molecule

Platform
small molecule
Targets
KRAS
Originator
Amgen
Sponsor
Amgen

Names

NameTypeSource
sotorasibpreferred name, INNcurator, ncit
Lumakrasbrandfda
Lumykrasbrandpress
AMG 510codencit

Cross-references

NCI Thesaurus
C154287
Wikidata
Q75175937
FDA UNII
2B2VM6UC8G

Approvals

No regulatory approval recorded.

Clinical trials (71)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07874737Mitoxantrone Hydrochloride Liposome Combined With Cladribine And Sotorasib For Relapsed Refractory Acute Myeloid LeukemiaNot yet recruitingPhase 22026-122028-1220Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)
NCT07543172CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung CancerNot yet recruitingPhase 22026-10-152029-06-0129Advanced Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8
NCT07012031Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C MutationRecruitingPhase 1/22026-06-172027-06-1437Locally Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8
NCT07318389ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal CancerRecruitingEarly phase 12026-04-222027-11-14100Dynamic Tumor Resistance; Metastatic Colorectal Cancer
NCT07563738A 2-part Phase 1/2 Open-label Trial on ODM-212RecruitingPhase 1/22026-03-272029-09229Mesothelioma; NSCLC (Advanced Non-small Cell Lung Cancer); Pancreatic Cancer
NCT07172919A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C MutationRecruitingPhase 22026-01-022028-07-0114Advanced Solid Tumors
NCT071248845-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced UnresectabNot yet recruitingPhase 22025-08-312030-06-30300Colorectal Carcinoma; KRAS G12C Mutation; Unresectable Colorectal Cancer
NCT07143513Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer PatientsCompleted2025-08-112025-12-07102Non-Small Cell Lung Cancer
NCT06892054Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic AdenocarcinomaRecruitingPhase 12025-08-082030-08-0815Pancreatic Adenocarcinoma
NCT06068153AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLCWithdrawnPhase 22025-032026-09-300KRAS G12C; Metastatic Non Small Cell Lung Cancer
NCT06804824A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid TumorsRecruitingPhase 12025-02-252027-08-01220Advanced Solid Tumors
NCT06807619A Study of Sotorasib in People With Brain TumorsRecruitingPhase 12025-01-292028-0116Brain Tumor
NCT06659341A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C MutationRecruitingPhase 12024-11-082027-11-30104Advanced Solid Tumors Harboring KRAS G12C Mutation
NCT06497556A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung CancerActive not recruitingPhase 32024-09-232026-05-19338KRAS G12C Lung Cancer; Non-Small Cell Lung Cancer
NCT06333951Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).Active not recruitingPhase 12024-09-172026-10-3149Non-small Cell Lung Cancer; Thoracic Tumors
NCT06582771A Study of Sotorasib in People With Non-Small Cell Lung CancerRecruitingPhase 22024-08-302027-0839Non Small Lung Cancer
NCT06532149ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung CancerUnknown2024-08-052026-09-0580Erectile Dysfunction; Hypogonadism, Male; NSCLC Stage IV; Sex Disorder
NCT05638295Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)Active not recruitingPhase 22024-08-012028-12-31105Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm
NCT06252649Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C MutationRecruitingPhase 32024-07-172028-09-25450Metastatic Colorectal Cancer
NCT06061523A Clinical Trial to Evaluate Bioavailability and Effect of Food for Sotorasib in Healthy ParticipantsWithdrawnPhase 12024-07-152024-09-090Healthy Participants
NCT06249282Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung CancerRecruitingPhase 12024-04-242026-11-2415Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8
NCT05815186Ladarixin With Sotorasib in Advanced NSCLC - Phase IIWithdrawnPhase 22024-042025-040Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
NCT06333678A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)TerminatedPhase 22024-03-202026-01-2710Non-Small Cell Lung Cancer
NCT05920356A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)RecruitingPhase 32023-11-162027-06-30750Non-Small Cell Lung Cancer (NSCLC)
NCT06314763Rivaroxaban Sotorasib Interaction StudyCompletedPhase 42023-11-092024-03-2121Drug Drug Interaction Study
NCT06127940K-SAB Trial - Sotorasib Followed by SBRT to 1-3 Lesions in Advanced NSCLC With KRASG12C MutationUnknownPhase 12023-10-152025-06-0120Non-small Cell Lung Cancer Metastatic
NCT05815173Ladarixin With Sotorasib in Advanced NSCLCRecruitingPhase 12023-08-012027-0840Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
NCT05993455A Phase 2 Basket Trial in Which Patients With Advanced Solid Tumors Carrying the KRAS G12C mUtation Receive Treatment With a Combination of Sotorasib and PanitumumabUnknownPhase 22023-07-032023-09-0424Efficacy
NCT05845450Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)RecruitingPhase 22023-05-112027-05197Colorectal Cancer; Resectable Colorectal Carcinoma
NCT05564377Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingPhase 22023-04-072030-07-012900Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Malignant Solid Neoplasm; Malignant Female Reproductive System Neoplasm; Metastatic HER2-Negative Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Unresectable HER2-Negative Breast Carcinoma; Unresectable Malignant Solid Neoplasm
NCT05631249Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12CRecruitingPhase 22022-12-132027-12-1240KRAS P.G12C; Non Small Cell Lung Cancer
NCT05374538VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung CancerTerminatedPhase 12022-11-092023-08-263Non-small Cell Lung Cancer
NCT05251038Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas CancerWithdrawnPhase 1/22022-09-132023-01-310KRAS P.G12C; Metastatic Pancreatic Cancer; Pancreatic Cancer; Unresectable Pancreatic Cancer
NCT05451056An Open-label, Phase 2trial of Sotorasib in KRAS G12C-mutant Non-small-cell Lung Cancer(NSCLC) Patients and a Translational Study to Find Acquired Resistance Mechanism to SotorasibUnknownPhase 22022-08-012026-0137Non Small Cell Lung Cancer
NCT05497557A Study to Evaluate the Impact of Omeprazole on the Pharmacokinetics of Sotorasib Co-administered With an Acidic Beverage in Healthy VolunteersCompletedPhase 12022-07-142022-09-0816Healthy Volunteers
NCT05400577Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLCWithdrawnPhase 22022-07-132024-01-010Non-Small Cell Lung Cancer
NCT05480865SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C MutationTerminatedPhase 12022-07-062024-08-2228Metastatic NSCLC; Metastatic Solid Tumor; Non Small Cell Lung Cancer; Solid Tumor, Adult
NCT05180422A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain MetastasisWithdrawnPhase 1/22022-06-152023-01-310Non Small Cell Lung Cancer
NCT05311709Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With ComorbiditiesUnknownPhase 22022-05-302024-10-01100Cancer; Cancer, Lung; Lung Cancer; Lung Cancer Stage IV; Mutation; NSCLC Stage IV; NSCLC, Stage III
NCT05198934Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C MutationCompletedPhase 32022-04-192025-07-16160Colorectal Cancer (CRC)
NCT05074810Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC PatientsActive not recruitingPhase 1/22022-04-122026-06153KRAS Activating Mutation; Non Small Cell Lung Cancer
NCT05118854A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C MutationActive not recruitingPhase 22022-03-302027-10-2013Lung Cancer
NCT05398094Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapyRecruitingPhase 22022-03-212027-12-3119KRAS P.G12C; Non-small Cell Lung Cancer Stage III
NCT05327491A Study in Healthy Volunteers to Compare the Pharmacokinetics of Sotorasib Administered as 1 or 2 TabletsCompletedPhase 12022-03-212022-07-17146Healthy Participants
NCT05313009Tarlox and Sotorasib in Patients With KRAS G12C MutationsTerminatedPhase 1/22022-03-072023-07-075Non-Small Cell Lung Cancer
NCT05273047RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLCUnknown2022-03-012023-08-30458KRAS P.G12C; Nsclc
NCT04933695A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line TreatmentTerminatedPhase 22022-01-282025-05-2842Non-small Cell Lung Cancer
NCT05054725Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard TherapiesCompletedPhase 22021-12-302024-07-0347Non-Small Cell Lung Cancer
NCT05036291A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid TumorsTerminatedPhase 12021-10-012025-09-2425Advanced Solid Tumor
NCT04959981A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLCCompletedPhase 12021-09-022023-04-2724Advanced Non-squamous Non-small-cell Lung Cancer
NCT05045638Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy ParticipantsCompletedPhase 12021-08-202021-10-1013Healthy Participants
NCT05048784A Study to Compare the Pharmacokinetics of Two Different Tablets of Sotorasib in Healthy ParticipantsCompletedPhase 12021-08-162022-02-18145Healthy Participants
NCT04892017Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid TumorsTerminatedPhase 12021-06-152026-03-3091Advanced Solid Tumor; Metastatic Solid Tumor; Non-Small Cell Lung Cancer
NCT04887064Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic ImpairmentCompletedPhase 12021-04-222022-03-0920Hepatic Impairment
NCT04625647Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)Active not recruitingPhase 22021-04-162026-12-31116Lung Adenocarcinoma; Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
NCT04720976JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid TumorsCompletedPhase 1/22021-03-232023-12-1958NSCLC; Solid Tumor
NCT05599828A Study to Evaluate the Impact of Acid-reducing Agents on the Pharmacokinetics (PK) of AMG 510 in Healthy ParticipantsCompletedPhase 12020-07-172020-09-1314Healthy Participants
NCT04303780Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).CompletedPhase 32020-06-042022-08-02345KRAS p, G12c Mutated /Advanced Metastatic NSCLC
NCT04380753AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).CompletedPhase 12020-04-282021-12-3112Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
NCT05578859A Study of the Absorption, Metabolism, and Excretion of [14C]-AMG 510 Following a Single Oral Dose in Healthy Male SubjectsCompletedPhase 12020-03-112020-03-248Healthy Subjects
NCT05571163A Study to Evaluate the Relative Bioavailability of AMG 510 Administered as Tablets and as a Water Dispersion in Healthy ParticipantsCompletedPhase 12020-03-062020-06-1413Healthy Participants
NCT05581992Study to Evaluate the Drug-drug Interaction Effect of Omeprazole on the Pharmacokinetics (PK) of AMG 510 in Healthy ParticipantsCompletedPhase 12020-01-062020-01-2614Healthy Participants
NCT04185883Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)Active not recruitingPhase 12019-12-172026-12-17610Advanced Solid Tumors; Kirsten Rat Sarcoma (KRAS) pG12C Mutation
NCT05568082A Study to Evaluate the Drug-drug Interaction Effect of Itraconazole on the Pharmacokinetics (PK) of AMG 510 in Healthy ParticipantsCompletedPhase 12019-12-032019-12-1714Healthy Participants
NCT05581758A Study to Assess the Effect of Food on the Pharmacokinetics (PK) of AMG 510 in Healthy ParticipantsCompletedPhase 12019-11-142019-11-2514Healthy Participants
NCT05550129Study to Evaluate the Drug-drug Interactions Between Metformin and AMG 510 in Healthy ParticipantsCompletedPhase 12019-11-132019-11-2513Healthy Volunteers
NCT05598281Study to Evaluate the Effect of AMG 510 on the Pharmacokinetics (PK) of Digoxin in Healthy ParticipantsCompletedPhase 12019-11-052019-11-1914Healthy Participants
NCT05577624A Study to Evaluate the Drug-drug Interaction Effect of Rifampin on the Pharmacokinetics of AMG 510 in Healthy ParticipantsCompletedPhase 12019-11-052019-12-0114Healthy Participants
NCT04092673Study of eFT226 in Subjects With Selected Advanced Solid Tumor MalignanciesUnknownPhase 1/22019-10-252024-12-3130Solid Tumor, Adult
NCT03600883A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)CompletedPhase 1/22018-08-272026-05-29713KRAS p.G12C Mutant Advanced Solid Tumors
NCT04667234Expanded Access of SotorasibNo longer availableLocally Advanced Metastatic NSCLC; Locally Advanced Unresectable NSCLC; Non Small-cell Lung Cancer

Recent changes

SeenTrialChangeDetailTitle
2026-11-12NCT06659341completion slipped2027-04-26 → 2027-11-30A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation
2026-11-12NCT07874737new trialMitoxantrone Hydrochloride Liposome Combined With Cladribine And Sotorasib For Relapsed Refractory Acute Myeloid Leukemia

Clinical papers

PubMedTitleJournalYearLinked by
PMID 40353648Combination therapy of sotorasib and docetaxel overcomes resistance to sotorasib alone in KRAS G12C mutant lung adenocarcinoma.Journal of chemotherapy (Florence, Italy)2026name in title: sotorasib
PMID 41539179Targeting driver mutations in lung cancer with interstitial pneumonia: A nationwide study in Japan.European journal of cancer (Oxford, England : 1990)2026name in abstract: sotorasib
PMID 41552958No relevant pharmacokinetic interaction between the KRAS G12C inhibitor sotorasib and the direct oral anticoagulant rivaroxaban in healthy subjects.International journal of cancer2026cited by trial NCT06314763
PMID 41811505Clinically actionable molecular alterations in Rb-retained small cell lung carcinoma variants.Virchows Archiv : an international journal of pathology2026name in abstract: sotorasib
PMID 41907639Durable response to sotorasib-based combination therapy in advanced lung adenocarcinoma harboring KRAS G12C and STK11 mutations: a case report.Frontiers in oncology2026name in title: sotorasib
PMID 41963020A 71-Year-Old Woman With Dyspnea and Hypoxemia After Liver Metastases Cryoablation.Chest2026name in abstract: sotorasib
PMID 42069451Sotorasib plus panitumumab and 5-fluorouracil in first-line treatment of patients with unresectable KRAS G12C mutated colorectal cancer unfit for a doublet/triplet chemotherapy: ENGIC 01 - PRODIGE 107 - FFCD 2306 - COLOSOTO trial.Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver2026name in title: sotorasib
PMID 42173791Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic Colorectal Cancer.Clinical colorectal cancer2026name in title: sotorasib
PMID 42293289Lung Adenocarcinoma Developing Pleomorphic Carcinoma With ERBB3 Amplification After Acquired Resistance to Sotorasib: A Case Report.JTO clinical and research reports2026name in title: sotorasib
PMID 42405535Durable response to sotorasib in KRAS G12C-mutant intrahepatic cholangiocarcinoma: a case report.The oncologist2026name in title: sotorasib
PMID 42428178Durable Response to Sotorasib Plus Panitumumab in NRAS G12C-Mutated, Microsatellite Instability-High (MSI-H) Rectal Cancer Refractory to Immunotherapy.Cureus2026name in title: sotorasib
PMID 42474245First report of dual KRAS Y96C/Y96S resistance mutations detected by liquid biopsy in KRAS G12C-mutant metastatic colorectal cancer.The oncologist2026name in abstract: sotorasib
PMID 42523592Transformation from lung adenocarcinoma to pulmonary giant cell carcinoma following targeted therapy: a case report.Frontiers in oncology2026name in abstract: sotorasib
PMID 42617424Safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer in the CodeBreaK 101 phase Ib study.ESMO open2026name in title: sotorasib
PMID 42630346Pulmonary carcinoid harboring a KRAS G12C mutation identified through comprehensive genomic profiling and responding to sotorasib: A case report.Rare tumors2026name in title: sotorasib
PMID 42756523Response to Sotorasib in a patient with recurrent KRAS G12C-mutated low-grade serous ovarian cancer: a case report and literature review.Gynecologic oncology reports2026name in title: sotorasib
PMID 42814800FAK inhibitor and RAF/MEK clamp avutometinib enhance KRAS G12C inhibitor efficacy in preclinical models of non-small cell lung cancer.Science translational medicine2026cited by trial NCT05074810
PMID 42891951Dose-Dependent Intracranial Response to Sotorasib in KRASG12C-Mutated Lung Cancer Brain Metastases: A Case Report.Oncology research and treatment2026name in title: sotorasib
PMID 42929675Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC.The New England journal of medicine2026cited by trial NCT06497556
PMID 42972108Neoadjuvant botensilimab with or without balstilimab in pMMR and dMMR colon cancer: the phase 2 UNICORN trial.Nature medicine2026cited by trial NCT05845450
PMID 39230186Relative Bioavailability of Sotorasib Following Administration as a Water Dispersion to Healthy Subjects and Compatibility With Enteral Administration.Clinical pharmacology in drug development2025name in title: sotorasib
PMID 39231674First Reported Case of Pure Red Cell Aplasia Related to Sotorasib.Internal medicine (Tokyo, Japan)2025name in title: sotorasib
PMID 39604046Impact of Acid-Reducing Agents on Sotorasib Pharmacokinetics and Potential Mitigation of the Impact by Coadministration With an Acidic Beverage.Clinical pharmacology in drug development2025cited by trial NCT05497557
PMID 39752885Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer.Journal of the National Comprehensive Cancer Network : JNCCN2025cited by trial NCT06252649
PMID 39777405Impact of Sotorasib, a KRAS G12C Inhibitor, on the Pharmacokinetics and Therapeutic Window of Digoxin, a P-Glycoprotein Substrate.Clinical pharmacology in drug development2025cited by trial NCT05598281
PMID 39828218A Single-Arm Phase 2 Study of Sotorasib Plus Carboplatin and Pemetrexed in Patients With Advanced Nonsquamous NSCLC With KRAS G12C Mutation (WJOG14821L, SCARLET).Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2025name in title: sotorasib
PMID 39970524Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study.European journal of cancer (Oxford, England : 1990)2025name in title: sotorasib
PMID 40110764Overcoming amplification-mediated resistance to sotorasib by dose re-escalation in KRAS G12C mutant NSCLC: a case report.The oncologist2025name in title: sotorasib
PMID 40215429Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2025name in title: sotorasib
PMID 40277845Successful Management of Acquired von Willebrand Syndrome Associated with Monoclonal Gammopathy of Undetermined Significance After Sotorasib Treatment in a Patient with Non-Small-Cell Lung Carcinoma.Hematology reports2025name in title: sotorasib
PMID 40333694JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies.Clinical cancer research : an official journal of the American Association for Cancer Research2025cited by trial NCT04720976
PMID 40542959Matching-Adjusted Indirect Comparison of Sotorasib Versus Adagrasib in Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation.Advances in therapy2025name in title: sotorasib
PMID 40774040Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial.Lung cancer (Amsterdam, Netherlands)2025name in title: sotorasib
PMID 40812325Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial.The Lancet. Oncology2025name in title: sotorasib
PMID 40831448Clinical Impact of Hepatic Impairment on the Pharmacokinetics of Sotorasib and Its Major Metabolites: Implications for Dose Adjustment.Journal of clinical pharmacology2025name in title: sotorasib
PMID 40866105Sotorasib provides a durable response in high-grade metastatic ovarian serous adenocarcinoma harbouring KRAS G12C mutation.BMJ case reports2025name in title: sotorasib
PMID 41114813Diffuse Large B-cell lymphoma in a Ras-Associated Autoimmune Leukoproliferative Disorder (RALD).Annals of hematology2025name in abstract: sotorasib
PMID 41355935Unlocking New Treatment Possibilities for Metastatic Endometrial Cancer With KRAS G12C Mutation.Case reports in oncological medicine2025name in abstract: sotorasib
PMID 41410376Marked Reduction in Tacrolimus and Everolimus Blood Levels Associated With Sotorasib: A Critical Drug Interaction in a Kidney Transplant Recipient.Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation2025name in title: sotorasib
PMID 38177853Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial.Nature medicine2024name in title: sotorasib
PMID 38269310Drug-induced lung injury in a patient treated with prior atezolizumab and subsequent sotorasib: A case report.Respirology case reports2024name in title: sotorasib
PMID 38299192The First Case Report of Effective Treatment With Sotorasib for Metastatic Atypical Lung Carcinoid Harboring KRAS G12C Mutation and Aggressive Disseminated Lung Metastasis: A Case Report.JTO clinical and research reports2024name in title: sotorasib
PMID 38377774Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany.European journal of cancer (Oxford, England : 1990)2024name in title: sotorasib
PMID 38421129Effect of Strong CYP3A4 Inhibition, CYP3A4 Induction, and OATP1B1/3 Inhibition on the Pharmacokinetics of a Single Oral Dose of Sotorasib.Clinical pharmacology in drug development2024name in title: sotorasib
PMID 38451823Twelve-month progression-free survival with sotorasib and panitumumab in KRAS G12C mutant metastatic colorectal cancer.Anti-cancer drugs2024name in title: sotorasib
PMID 38550295Prolonged Cancer Control With Adagrasib in Patients With Metastatic, KRASG12C-Mutated NSCLC After Sotorasib-Induced Hepatotoxicity: A Case Report.JTO clinical and research reports2024name in title: sotorasib
PMID 38614068Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal.Lung cancer (Amsterdam, Netherlands)2024name in title: sotorasib
PMID 38615940Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2024name in title: sotorasib
PMID 38711902Sotorasib as first-line therapy in patients with advanced non-small cell lung cancer with KRAS gene mutations combined with brain metastases: a case report.AME case reports2024name in title: sotorasib
PMID 38799516Mixed response to the first-line treatment of KRAS G12C inhibitor, sotorasib, in non-small cell lung cancer: A brief report.Clinical case reports2024name in title: sotorasib
PMID 38917307Sotorasib as Fourth-Line Treatment in Pancreatic Cancer: A Case Report and Literature Review.Rhode Island medical journal (2013)2024name in title: sotorasib
PMID 39016337Impact of a High-Fat Meal on the Pharmacokinetics of Sotorasib, a KRAS G12C Inhibitor.Clinical pharmacology in drug development2024name in title: sotorasib
PMID 39016668A case of hepatoid adenocarcinoma of the lung harboring KRAS G12C responded favorably to sotorasib.Pathology international2024name in title: sotorasib
PMID 39018528Sotorasib for Vascular Malformations Associated with KRAS G12C Mutation.The New England journal of medicine2024name in title: sotorasib
PMID 39029295Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC.European journal of cancer (Oxford, England : 1990)2024name in title: sotorasib
PMID 39074423Treatment patterns and outcomes in KRASG12C-positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study.Lung cancer (Amsterdam, Netherlands)2024name in abstract: sotorasib
PMID 39247747Returning from the afterlife? Sotorasib treatment for advanced KRAS mutant lung cancer: A case report.World journal of clinical cases2024name in title: sotorasib
PMID 39303400Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation.Lung cancer (Amsterdam, Netherlands)2024name in title: sotorasib
PMID 39470877Real-World Evaluation of Treatment Patterns, Healthcare Costs, and Healthcare Resource Utilization Among Patients with Non-small Cell Lung Cancer in the US Receiving Sotorasib.Advances in therapy2024name in title: sotorasib
PMID 39474565Sotorasib in KRAS p.G12C-Mutated Pulmonary Sarcomatoid Carcinoma: Therapeutic Efficacy of a KRAS Inhibitor in Symptomatic Brain Metastases.Case reports in oncology2024name in title: sotorasib
PMID 36546651Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer.The New England journal of medicine2023cited by trial NCT03600883
PMID 36619890Rapid Response to Sotorasib of a Patient With KRAS G12C-Mutated Lung Cancer With Cancer-Associated Disseminated Intravascular Coagulation: A Case Report.JTO clinical and research reports2023name in title: sotorasib
PMID 36764316Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial.Lancet (London, England)2023cited by trial NCT04303780
PMID 36841727A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer.Clinical lung cancer2023name in abstract: sotorasib
PMID 37008835Sotorasib as First-Line Treatment for Advanced KRAS G12C-Mutated Non-Small Cell Lung Carcinoma: A Case Report.Case reports in oncology2023name in title: sotorasib
PMID 37098232Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2023name in title: sotorasib
PMID 37131995De Novo SCLC Transformation From KRAS G12C-Mutated Lung Adenocarcinoma With Excellent Response to Sotorasib: A Case Report.JTO clinical and research reports2023name in title: sotorasib
PMID 37217096Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2023name in title: sotorasib
PMID 37384866Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non-Small Cell Lung Cancer.JCO precision oncology2023name in title: sotorasib
PMID 37408855Activity of sotorasib against brain metastases from NSCLC harboring KRAS p.G12C mutation: a case report.Drug target insights2023name in title: sotorasib
PMID 37870968Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C.The New England journal of medicine2023name in title: sotorasib
PMID 37886215Tolerability of sotorasib for KRAS positive lung adenocarcinoma patient with pre-existing interstitial pneumonia; A case report.Respiratory medicine case reports2023name in title: sotorasib
PMID 38044989Case Report: Case series: association between blood concentration and side effects of sotorasib.Frontiers in oncology2023name in title: sotorasib
PMID 38096473Efficacy and Tolerability of Osimertinib and Sotorasib Combination Treatment for Osimertinib Resistance Caused by KRAS G12C Mutation: A Report of Two Cases.JCO precision oncology2023name in title: sotorasib
PMID 34919824Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial.The Lancet. Oncology2022name in title: sotorasib
PMID 35643747Successful Use of Sotorasib in a Patient With End-Stage Renal Disease on Dialysis With Metastatic Lung Adenocarcinoma: A Case Report.Clinical lung cancer2022name in title: sotorasib
PMID 35735665The Role of Serial Liquid Biopsy in the Management of Metastatic Non-Small Cell Lung Cancer (NSCLC).Clinics and practice2022name in abstract: sotorasib
PMID 36157699Sotorasib Shows Intracranial Activity in Patients with KRAS G12C-Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases.Case reports in oncology2022name in title: sotorasib
PMID 36353445Molecular docking analysis reveals differential binding affinities of multiple classes of selective inhibitors towards cancer-associated KRAS mutants.3 Biotech2022name in abstract: sotorasib
PMID 36388799Complete response to sotorasib as neoadjuvant treatment in patient with locally advanced primary pulmonary sarcoma harboring KRAS mutation: a case report.Annals of translational medicine2022name in title: sotorasib
PMID 36471683Remarkable Intracranial Response to Sotorasib in a Patient With KRAS G12C-Mutated Lung Adenocarcinoma and Untreated Brain Metastases: A Case Report.JTO clinical and research reports2022name in title: sotorasib
PMID 34096690Sotorasib for Lung Cancers with KRAS p.G12C Mutation.The New England journal of medicine2021name in title: sotorasib
PMID 34590053Severe Immune Checkpoint Inhibitor Hepatitis in KRAS G12C-Mutant NSCLC Potentially Triggered by Sotorasib: Case Report.JTO clinical and research reports2021name in title: sotorasib
PMID 31820981Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors.Journal of medicinal chemistry2020cited by trial NCT03600883
PMID 32955176KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.The New England journal of medicine2020name in title: sotorasib
PMID 31666701The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.Nature2019name in title: AMG 510

Other papers

Preclinical studies, reviews and other papers that name it, newest 100 shown.

PubMedTitleJournalYearLinked by
PMID 40770093NSD2 inhibitors rewire chromatin to treat lung and pancreatic cancers.Nature2026name in abstract: sotorasib
PMID 40776650Bioinformatics And Experimental Insights Into Sotorasib Resistance Mechanisms in Non-small-cell Lung Cancer.Anti-cancer agents in medicinal chemistry2026name in title: sotorasib
PMID 40971231Advances in pancreatic cancer early diagnosis, prevention, and treatment: The past, the present, and the future.CA: a cancer journal for clinicians2026name in abstract: sotorasib
PMID 40991960Optimizing KRAS Therapeutics for Non-Small Cell Lung Cancer.Annual review of medicine2026name in abstract: sotorasib
PMID 41165466Targeting CDK12/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C Inhibitors.Cancer research2026name in abstract: sotorasib
PMID 41191614A novel anticancer natural product SP09 selectively targets KRAS-mutant NSCLC through LKB1/AMPK/mTOR modulation: implications for novel therapeutic development.Anti-cancer drugs2026name in abstract: sotorasib
PMID 41340466Activity of Direct KRAS(G12C) Inhibitors in Preclinical Models of Pediatric Cancer.Molecular cancer therapeutics2026name in abstract: sotorasib
PMID 41348990Opportunities for Harmonization of US Food and Drug Administration Regulatory Decisions Exemplified by the Traditional Approval of Sotorasib and Panitumumab for Colorectal Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2026name in title: sotorasib
PMID 41380450Flourishing innovation in KRAS targeting: Recent advances in medicinal chemistry strategies and future perspectives.Bioorganic chemistry2026name in abstract: sotorasib
PMID 41396253Targeted Therapies in Non-Small Cell Lung Cancer: A Contemporary Review.American journal of clinical oncology2026name in abstract: sotorasib
PMID 41419408Targeted and immunotherapy strategies in pancreatic ductal adenocarcinoma: Recent developments and insights.Hepatobiliary & pancreatic diseases international : HBPD INT2026name in abstract: sotorasib
PMID 41475546ANP32A-mediated histone 3 K27 acetylation is essential for sotorasib activity in KRAS-mutant non-small cell lung cancer.The Journal of biological chemistry2026name in title: sotorasib
PMID 41492050Development and Validation of the Novel, Fast Bioanalytical LC-MS/MS Technique for the Simultaneous Estimation of Sotorasib and Ondansetron: Application to In Vivo Pharmacokinetic Assessments.Biomedical chromatography : BMC2026name in title: sotorasib
PMID 41508946Advances in targeting KRAS mutations: A promising approach for the treatment of non‑small cell lung cancer (Review).Oncology reports2026name in abstract: sotorasib
PMID 41526435KRAS mutated lung adenocarcinoma responds to pan-ERBB and Aurora kinase inhibitors.NPJ precision oncology2026name in abstract: sotorasib
PMID 41529383Advances on drug therapy for KRASG12C-mutant non-small-cell lung cancer.Translational oncology2026name in abstract: sotorasib
PMID 41581311Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC.Lung cancer (Amsterdam, Netherlands)2026name in abstract: sotorasib
PMID 41585660Environmental Pollutants and Protein Destabilization in Lung Cancer: Anticancer Drug Strategies for Structural Stability.ACS omega2026name in abstract: sotorasib
PMID 41638869Tumor immune microenvironment facilitates resistance to KRAS G12C inhibitor sotorasib by altered PD-L1 expression.Journal for immunotherapy of cancer2026name in title: sotorasib
PMID 41652638NRAS and SREBF1 identified as mitophagy-associated risk genes for rheumatoid arthritis through interpretable machine learning and experimental validation studies.BMC rheumatology2026name in abstract: sotorasib
PMID 41654096Real-world evidence for 10 oncology drugs approved in the last 5 years: A comprehensive narrative synthesis.Critical reviews in oncology/hematology2026name in abstract: sotorasib
PMID 41654234Synthesis and characterization of bicyclo[1.1.0]butane amides and 5-methylene-3-azabicyclo[5.1.0]octan-4-ones as covalent modifiers.Bioorganic & medicinal chemistry letters2026name in abstract: sotorasib
PMID 41663526Therapeutic advances with KRASG12C inhibitors and combination strategies in non-small cell lung cancer brain metastases.Cancer gene therapy2026name in abstract: sotorasib
PMID 41665865Evaluating Post-Progression Survival in the Context of Progression-Free Survival Benefits: A Revisit of the CodeBreaK200 Design.Therapeutic innovation & regulatory science2026name in abstract: sotorasib
PMID 41670818Genomic alterations and their correlation with metabolic-related genes in lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026name in abstract: sotorasib
PMID 41671906Deep exploration of sotorasib-related hepatobiliary AEs: Based on FDA Adverse Event reporting system.Lung cancer (Amsterdam, Netherlands)2026name in title: sotorasib
PMID 41697749Cotargeting DNA topoisomerase II enhances efficacy of RAS-targeted therapy in KRAS-mutant cancer models.The Journal of clinical investigation2026name in abstract: sotorasib
PMID 41697929KRAS Inhibition in Non-Small Cell Lung Cancer with Central Nervous System Involvement: Current Evidence and Future Directions.Oncology research and treatment2026name in abstract: sotorasib
PMID 41784211A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science.Cancer investigation2026name in abstract: sotorasib
PMID 41786688Cetuximab co-treatment with KRAS G12C inhibitors fulzerasib and sotorasib in human KRAS G12C non-small cell lung cancer cells.Cell death discovery2026name in title: sotorasib
PMID 41808249Constitutive EGFR Activation Induced by PTPRR Downregulation Confers Resistance to KRAS Inhibitors.Cancer research communications2026name in abstract: sotorasib
PMID 41815506MET-Driven Resistance to Sotorasib in KRAS G12C-Mutant NSCLC and Response to Combined KRAS and MET Inhibition.JTO clinical and research reports2026name in title: sotorasib
PMID 41822354Tumor microenvironment-activated ferritin nanovector enables enhanced tumor delivery of KRASG12C inhibitors and degraders.Frontiers in cell and developmental biology2026name in abstract: sotorasib
PMID 41830517MRTX1133 suppresses ERK signaling but elicits context-dependent antiproliferative responses in KRAS (G12C) cancer cells.Molecular cancer therapeutics2026name in abstract: sotorasib
PMID 41839684Dual targeting of IGF-1R and K-RAS with natural phytochemicals for lung cancer therapy: an in-silico study.Journal, genetic engineering & biotechnology2026name in abstract: sotorasib
PMID 41856615[Clinical characteristics of 20 lung adenocarcinoma patients misdiagnosed as interstitial pneumonia].Zhonghua yi xue za zhi2026name in abstract: sotorasib
PMID 41888140Small-molecule degraders for oncogenic KRASG12C and pan-KRAS mutations.Nature communications2026name in abstract: sotorasib
PMID 41898563MicroRNA Mimics Based on the miR-15/107 Consensus Sequence Sensitise NSCLC Cells to Targeted Therapy.International journal of molecular sciences2026name in abstract: sotorasib
PMID 41915587Advancements in Sotorasib: A Comprehensive Review of its Efficacy in Non-small Lung Cancer Treatment.Recent patents on anti-cancer drug discovery2026name in title: sotorasib
PMID 41998662MXD4 enhances resistance to KRAS G12C-targeted therapy in lung adenocarcinoma by suppressing ACSL4-mediated ferroptosis.Respiratory research2026name in abstract: sotorasib
PMID 42002901Immunohistochemical Localization of Sotorasib-Protein Conjugates in the Rat Gastrointestinal Tract.Biological & pharmaceutical bulletin2026name in title: sotorasib
PMID 42003513Combining cutting edge computational and experimental methods for targeting KRAS mutations in non-small cell lung cancer.Expert opinion on drug discovery2026name in abstract: sotorasib
PMID 42006282Sotorasib in Advanced KRAS G12C-Mutated NSCLC: Results From the Global Expanded Access Program, Including Patients With Poor Performance Status and a History of CNS Metastases.JTO clinical and research reports2026name in title: sotorasib
PMID 42007639Galangin Overcomes Gefitinib and Sotorasib Resistance in Non-small Cell Lung Cancer by Inhibiting Efferocytosis.Journal of agricultural and food chemistry2026name in title: sotorasib
PMID 42007988ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window.Molecular cancer therapeutics2026name in abstract: sotorasib
PMID 42031346From G12C To pan-RAS: The expanding therapeutic landscape of KRAS-mutant NSCLC.Critical reviews in oncology/hematology2026name in abstract: sotorasib
PMID 42031711AURKA/PHB2 signaling drives acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant NSCLC.Cell death discovery2026name in abstract: sotorasib
PMID 42034368Clinical trajectory of KRAS G12C-mutated advanced non-small cell lung cancer: a single-center cohort study in Japan.Respiratory investigation2026name in abstract: sotorasib
PMID 42041157MRTX1133 Suppresses ERK Signaling but Elicits Context-Dependent Antiproliferative Responses in KRAS (G12C) Cancer Cells.Molecular cancer therapeutics2026name in abstract: sotorasib
PMID 42055521KRAS G12C inhibitor outcomes in advanced non-small cell lung cancer by smoking history, performance status, and KEAP1 mutation status.Cancer treatment and research communications2026name in abstract: sotorasib
PMID 42056373Bioinformatics and computational exploration of novel inhibitors targeting KRAS G12C mutant protein in lung adenocarcinoma.Discover oncology2026name in abstract: sotorasib
PMID 42077604Emerging precision therapeutics for pancreatic ductal adenocarcinoma: KRAS and beyond.Therapeutic advances in medical oncology2026name in abstract: sotorasib
PMID 42090290Accumulated sotorasib-bound KRASG12C reactivates the MAPK pathway and drives sotorasib resistance via the DHX9-RAC1-PAK1 axis.Cell reports2026name in title: sotorasib
PMID 42090632Targeting KRAS G12C in Rare Mesonephric Carcinoma of the Cervix: A Promising Response to Sotorasib.JCO precision oncology2026name in title: sotorasib
PMID 42094443Dual inhibition of GTP-bound (ON) and GDP-bound (OFF) KRASG12C suppresses PI3Kα and leads to potent tumor inhibition.bioRxiv : the preprint server for biology2026name in abstract: sotorasib
PMID 42098425Evaluating the efficacy of G12C inhibitors in conjunction with Gamma Knife radiosurgery for KRAS-mutant non-small cell lung cancer brain metastases.Journal of neuro-oncology2026name in abstract: sotorasib
PMID 42099550Exploring genomic analysis and methylome profiling in longitudinal series of p.G12C KRAS mutated NSCLC patients treated with sotorasib.The journal of liquid biopsy2026name in title: sotorasib
PMID 42114275KRAS G12C-mutant non-small cell lung cancer: A practical guide for clinicians.Cancer treatment reviews2026name in abstract: sotorasib
PMID 42122163Discovery of Structurally Distinct Covalent KRAS G12C Inhibitor Scaffolds Through Large-Scale In Silico Screening and Experimental Validation.Cancers2026name in abstract: sotorasib
PMID 42124568mSWI/SNF complex inhibition sensitizes KRAS-mutant lung cancers to targeted therapies via epithelial-mesenchymal subversion.bioRxiv : the preprint server for biology2026name in abstract: sotorasib
PMID 42144204Sotorasib induces intestinal epithelial injury through suppression of the cAMP/PKA/CREB signaling axis.Biochemical pharmacology2026name in title: sotorasib
PMID 42170277Pre-clinical efficacy of trastuzumab deruxtecan plus sotorasib in KRASG12C -mutant non-small cell lung cancer and exploratory HER2 profiling in human tumors.Translational lung cancer research2026name in title: sotorasib
PMID 42187721Disrupting the Undruggable: Emerging Modalities for Targeting Protein-Protein Interactions in Oncology.Biology2026name in abstract: AMG 510
PMID 42190605Sotorasib combined with 3-methyladenine for the treatment of KRAS G12C-mutant pancreatic cancer and its underlying mechanisms.Translational oncology2026name in title: sotorasib
PMID 42224643Standard Versus Reduced Sotorasib Dosing in KRAS G12C-Mutated Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis-Have We Answered the Dosing Question?JCO oncology practice2026name in title: sotorasib
PMID 42229337Real-world comparative effectiveness of sotorasib versus docetaxel monotherapy in second line and beyond for advanced or metastatic non-small cell lung cancer: A national database analysis from England.Lung cancer (Amsterdam, Netherlands)2026name in title: sotorasib
PMID 42279426Pan-RAS Inhibitors: Expanding Therapeutic Potential and Evading Resistance.Cancers2026name in abstract: sotorasib
PMID 42282123Study of the blood-brain barrier-penetrating KRAS G12C inhibitor JMKX1899 in KRAS G12C-mutated NSCLC with brain metastases.Journal of the National Cancer Center2026name in abstract: AMG 510
PMID 42283833Drug repurposing in KRAS G12C-mutant NSCLC: a focus on resistance mechanisms and clinical strategies.Naunyn-Schmiedeberg's archives of pharmacology2026name in abstract: sotorasib
PMID 42294187Machine Learning-Driven Drug Repurposing for KRAS G12C and KRAS G12D Inhibition.ACS omega2026name in abstract: sotorasib
PMID 42336204Adaptive Feedback Signaling Through the FAK/SRC Pathway Promotes KRAS G12C Inhibitor Resistance.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2026name in abstract: sotorasib
PMID 42386216Targeting KRAS for cancer therapy.British journal of pharmacology2026name in abstract: sotorasib
PMID 42393288Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer.Oncogene2026name in abstract: sotorasib
PMID 42415848M1C IS NECESSARY FOR DARAXONRASIB RESISTANCE OF NSCLC KRAS(G12C) MUTANT CELLS.bioRxiv : the preprint server for biology2026name in abstract: sotorasib
PMID 42446418Expanding Addressable KRAS Mutations through the Structure- and Property-Based Design of Dual-State (GDP/GTP), Reversible Pan-KRAS Inhibitors.Journal of medicinal chemistry2026name in abstract: sotorasib
PMID 42448954KRAS-mediated CCDC6 degradation drives xCT upregulation and ferroptosis evasion.Apoptosis : an international journal on programmed cell death2026name in abstract: sotorasib
PMID 42450070Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies.International journal of molecular sciences2026name in abstract: sotorasib
PMID 42511798KRAS G12C-Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone.International journal of molecular sciences2026name in abstract: sotorasib
PMID 42514855RAS Inhibitors: Changing the Paradigm from the Undruggable.Pharmaceutics2026name in abstract: sotorasib
PMID 42536138Radio-sensitization of mutated KRAS G12C non-small cell lung cancer with KRAS G12C tyrosine kinase inhibitor and carbon ions irradiation.Molecular and cellular biochemistry2026name in abstract: sotorasib
PMID 42551924[Therapeutic Strategies Targeting the KRAS G12C Mutation-Current Landscape and Future Directions].Gan to kagaku ryoho. Cancer & chemotherapy2026name in abstract: sotorasib
PMID 42551925[Development of Therapies Targeting Non-G12C KRAS Mutations (Focusing on G12D and Pan-RAS)].Gan to kagaku ryoho. Cancer & chemotherapy2026name in abstract: sotorasib
PMID 42551926[Targeting KRAS-Mutant Cancers-Therapeutic Strategies and Mechanisms of Resistance to RAS Inhibitors].Gan to kagaku ryoho. Cancer & chemotherapy2026name in abstract: sotorasib
PMID 42557306M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitors.Oncogene2026name in abstract: sotorasib
PMID 42593915Property-Biased Covalent DNA-Encoded Library Screening Enabled the Discovery of AM-8719, A Structurally Novel, CNS-Penetrant KRAS G12C Inhibitor.Journal of medicinal chemistry2026name in abstract: sotorasib
PMID 42607542Anticancer effects of an XPO1 inhibitor (selinexor) with sotorasib following omeprazole preconditioning in KRAS G12C-mutant non-small cell lung cancer cells in vitro and in a mouse tumor xenograft.Neoplasia (New York, N.Y.)2026name in title: sotorasib
PMID 42611092KRAS G12C-mutated Metastatic Colorectal Cancer: Current Therapeutic Strategies and Future Directions.Journal of gastrointestinal cancer2026name in abstract: sotorasib
PMID 42622884KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms.Medical oncology (Northwood, London, England)2026name in abstract: sotorasib
PMID 42653726Development of a PK/PD-Efficacy Modeling Framework for Covalent Inhibitors.Pharmaceuticals (Basel, Switzerland)2026name in abstract: sotorasib
PMID 42688109Targeting KRASG12C in non-small cell lung cancer: evidence from randomized clinical trials and future therapeutic strategies.Frontiers in oncology2026name in abstract: sotorasib
PMID 42699034Theoretical study of KRAS G12C secondary mutations influencing inhibitor resistance.Biophysics and physicobiology2026name in abstract: sotorasib
PMID 42703145Sotorasib and Panitumumab: A breakthrough in the treatment of KRAS-mutated mCRC.JPMA. The Journal of the Pakistan Medical Association2026name in title: sotorasib
PMID 42707601KRAS mutations as architects of the tumor immune microenvironment: implications for combination therapies.Frontiers in oncology2026name in abstract: sotorasib
PMID 42716336An Application of Iterative Health Economic Evaluation: An Update on the Early Cost Effectiveness of Whole Genome Sequencing in Advanced Non-small Cell Lung Cancer.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research2026name in abstract: sotorasib
PMID 42720810Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers.Medical oncology (Northwood, London, England)2026name in abstract: sotorasib
PMID 42726935KRAS-G12C inhibition-induced enrichment of MHC-Ihigh immune-active tumor cells directs immune-effector TME development to augment therapeutic efficacy.Cancer immunology research2026name in abstract: sotorasib
PMID 42749446Computational identification and characterization of high-risk human KRAS nsSNPs: Impacting structure, ligand binding, and cancer prognosis.Journal, genetic engineering & biotechnology2026name in abstract: sotorasib
PMID 42759542Targeting KRAS-Mutant Lung Cancers.Journal of the National Comprehensive Cancer Network : JNCCN2026name in abstract: sotorasib
PMID 42771901Real-world Experience with Sotorasib in KRAS G12C-Mutated Advanced Non-small Cell Lung Cancer: Clinical Outcomes and Tolerability in the UK.Clinical oncology (Royal College of Radiologists (Great Britain))2026name in title: sotorasib
PMID 42860233Blockade of mutant RAS oncogenic signaling: A 2026 update.Pharmacological research2026name in abstract: sotorasib

NIH grants

ProjectTitleOrganisationPIYearsLinked by
F30CA281272Maximizing Selective Inhibition of Clinically Observed MET MutantsSTATE UNIVERSITY NEW YORK STONY BROOKOUTHWAITE, IAN2024–2026name in abstract: sotorasib
K01CA313805Targeting a novel covalent RAS dimer in RASQ61 mutants-driven cancersUT SOUTHWESTERN MEDICAL CENTERZHOU, ZHIWEI2026–2026name in abstract: sotorasib
K22CA276357Targeted degradation of KRAS oncoproteins triggers antitumor immunity and abolishes lung tumorUNIVERSITY OF PITTSBURGH AT PITTSBURGHZHANG, HUA2024–2026name in abstract: sotorasib
P30CA016672Stem Cell Biology & Cellular Therapy ProgramUNIVERSITY OF TX MD ANDERSON CAN CTRSHPALL, ELIZABETH J2019–2026name in abstract: sotorasib
R01CA131261Studying the initiation, progression and therapy of lung cancer in mouse modelsUTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAHMCMAHON, MARTIN2023–2026name in abstract: sotorasib
R01CA270240Proteostasis Reprogramming in Mutant KRAS-Driven CancersUNIVERSITY OF TX MD ANDERSON CAN CTRCHEN, XI2023–2026name in abstract: sotorasib
R01CA279194Dissecting and targeting tumor-TME crosstalk to forestall acquired KRASG12C inhibitor resistance in NSCLC.UNIVERSITY OF TX MD ANDERSON CAN CTRSKOULIDIS, FERDINANDOS2023–2026name in abstract: sotorasib
R01CA279264Mechanisms of adaptation and resistance to emerging therapies for lung cancerSLOAN-KETTERING INST CAN RESEARCHLITO, PIRO2023–2026name in abstract: sotorasib
R01CA281295KRAS G12C: Kinetic and Redox Characterization of Covalent InhibitionUNIV OF NORTH CAROLINA CHAPEL HILLCAMPBELL, SHARON L2023–2026name in abstract: sotorasib
R01CA283049Novel approaches to target KEAP1 mutant tumorsNEW YORK UNIVERSITY SCHOOL OF MEDICINEPAPAGIANNAKOPOULOS, THALES2024–2026name in abstract: sotorasib
R01CA285743Synthetic lethal targeting of KRAS/KEAP1 co-mutant non-small cell lung cancerRUSH UNIVERSITY MEDICAL CENTERMAKI, CARL G2024–2026name in abstract: sotorasib
R01CA285926Targeting cytoplasmic SET oncoprotein by sphingolipid analog drugs for the induction of necroptosis to treat lung cancerMEDICAL UNIVERSITY OF SOUTH CAROLINAOGRETMEN, BESIM2024–2026name in abstract: sotorasib
R01CA296154Highly tumor-selective pan RAS inactivators for targeting oncogenic RAS-driven cancersUNIVERSITY OF PITTSBURGH AT PITTSBURGHLIU, SHIHUI2025–2026name in abstract: sotorasib
R01CA311659Covalent Inhibitors of Ras Q61 Mutations in CancerUNIVERSITY OF CALIFORNIA, SAN FRANCISCOHUANG, BENJAMIN2026–2026name in abstract: sotorasib
R21CA295906Targeting SMARCA2 to overcome resistance of SMARCA4-mutant lung cancer to KRAS G12C inhibitorsUNIVERSITY OF TX MD ANDERSON CAN CTRLISSANU, YONATHAN2025–2026name in abstract: sotorasib
R21CA296712Proximity-triggered, mutant-specific modification of K-Ras(G12C) with local polypharmaceutical releaseCOLD SPRING HARBOR LABORATORYMOSES, JOHN EDWARD2025–2026name in abstract: sotorasib
R35GM124637MIRA: Atropisomerism as an inspiration for drug discovery and new chemistrySTATE UNIVERSITY NEW YORK STONY BROOKGUSTAFSON, JEFFREY LOUIS2022–2026name in abstract: AMG 510
U54CA224083Research Project 2WASHINGTON UNIVERSITYLIM, KIAN-HUAT2023–2026name in abstract: sotorasib
K22CA276632Identification of resistance mechanisms to direct KRAS inhibition in pancreatic cancerUNIVERSITY OF CINCINNATIWATERS, ANDREW M2023–2025name in abstract: sotorasib
R01CA262469Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancerUNIVERSITY OF TX MD ANDERSON CAN CTRSKOULIDIS, FERDINANDOS2021–2025name in abstract: AMG 510
R21CA280163Expanding the targetable landscape in cancer with serine-targeting covalent ligandsUNIVERSITY OF CALIFORNIA BERKELEYZHANG, ZIYANG2024–2025name in abstract: sotorasib
R21CA286372The Role of the Tumor Microenvironment in Resistance to Oncogenic KRAS Inhibition in Lung CancerUNIVERSITY OF MICHIGAN AT ANN ARBORGALBAN, STEFANIE2024–2025name in abstract: sotorasib
R21CA297690Noncovalent interaction of mutant KRAS inhibitorsDUKE UNIVERSITYCHI, JEN-TSAN ASHLEY2025–2025name in abstract: sotorasib
R21CA302807Exploiting synthetic lethality to enhance KRAS inhibitor therapy of cancerNEW YORK UNIVERSITY SCHOOL OF MEDICINENEEL, BENJAMIN G.2025–2025name in abstract: sotorasib
R44AI177220Mitigation of Radiation Induced Gastrointestinal Syndrome.BCN BIOSCIENCES, LLCNORRIS, ANDREW JOHN2023–2025name in abstract: sotorasib
ZIABC011892Targeting RAS in Pediatric CancerDIVISION OF BASIC SCIENCES - NCIYOHE, MARIELLE2019–2025name in abstract: sotorasib
ZIASC006321Modulation of Therapeutic ResponseDIVISION OF CLINICAL SCIENCES - NCIMITCHELL, JAMES2024–2025name in abstract: AMG 510
F31CA261061Interrogating the role of mutant KRAS allelic imbalance and co-mutated genes in targeted therapy response of NSCLCWEILL MEDICAL COLL OF CORNELL UNIVDIAZ, BIANCA2021–2024name in abstract: AMG 510
F31CA261116Investigating KRAS Signaling and Autophagy Co-inhibition in KRAS-mutant Lung CancerUTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAHGHAZI, PHAEDRA2022–2024name in abstract: sotorasib
R37CA215427Clinical Translation of Nuclear Export Inhibitor in Metastatic Pancreatic CancerWAYNE STATE UNIVERSITYAZMI, ASFAR S2023–2024name in abstract: sotorasib
R42CA275425Molecular brush-conjugated antisense oligonucleotide as a pan-KRAS depletion agentPACDNA LLCZHANG, KE2022–2024name in abstract: sotorasib
R21CA267412Development of Novel Combination Strategies to Overcome Resistance to KRASG12C Inhibition in Colorectal CancersUNIVERSITY OF MICHIGAN AT ANN ARBORLEOPOLD, JUDITH S2022–2023name in abstract: AMG 510
R21CA282568Overcoming resistance to KRAS inhibitors through a fragment-based chemoproteomics approachH. LEE MOFFITT CANCER CTR & RES INSTHAURA, ERIC B.2023–2023name in abstract: sotorasib
F32CA250231Targeting MCL-1 dependent apoptotic vulnerability of KRAS-LKB1 NSCLCMASSACHUSETTS GENERAL HOSPITALLI, CHENDI2020–2022name in abstract: AMG 510
U54CA233306Preclinical studies of KRAS and EGFR mutations in lung cancer PDXsUNIVERSITY OF CALIFORNIA AT DAVISCARVAJAL CARMONA, LUIS GUILLERMO2022–2022name in abstract: sotorasib
R21CA252430Evaluating a Novel Autophagy Inhibitor in KRAS-Driven Lung CancerMICHIGAN STATE UNIVERSITYMACKEIGAN, JEFFREY PAUL2021–2021name in abstract: AMG 510

Notes

KRAS G12C (OFF-state covalent). Approved (US 2021 Lumakras; EU Lumykras).

How to cite

sotorasib (AXP000023.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000023.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.